Human Vγ9Vδ2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells.


Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
08 10 2021
Historique:
received: 17 07 2021
accepted: 02 08 2021
pubmed: 19 8 2021
medline: 19 11 2021
entrez: 18 8 2021
Statut: ppublish

Résumé

Human γδ T cells expressing Vγ9Vδ2 T cell receptors play a crucial role in the innate immune system and have an attracted interest as effector cells in adoptive cellular immunotherapy. However, the efficacy of adoptive cellular immunotherapy for the treatment of tumors requires overcoming the immunosuppressive microenvironment. αβ T cell inhibition in the tumor microenvironment is associated with programmed death-ligand 1 (PD-L1) expression level. Vγ9Vδ2 T cells (abbreviated as γδ T cells here) exert potent cytotoxic effects in various cancers; however, γδ T cell activity in relation to the level of PD-L1 expression in cancer cells remains unclear, and the association between the PD-1/PD-L1 axis and γδ T cell cytotoxicity needs to be investigated. In this study, PD-1 blockade did not increase the cytotoxicity of γδ T cells against PD-L1

Identifiants

pubmed: 34407491
pii: S0006-291X(21)01145-1
doi: 10.1016/j.bbrc.2021.08.005
pii:
doi:

Substances chimiques

B7-H1 Antigen 0
CD274 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

132-139

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The Authors have no conflicts of interest to disclose in regard to this study.

Auteurs

Mako Tomogane (M)

Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, Kyoto, Japan.

Yusuke Sano (Y)

Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, Kyoto, Japan.

Daiki Shimizu (D)

Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, Kyoto, Japan.

Teruki Shimizu (T)

Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Masatsugu Miyashita (M)

Department of Urology, Japanese Red Cross Society Kyoto Daini Hospital, Kyoto, Japan.

Yuki Toda (Y)

Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, Kyoto, Japan.

Shigekuni Hosogi (S)

Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, Kyoto, Japan.

Yoshimasa Tanaka (Y)

Center for Medical Innnovation, Nagasaki University, Nagasaki, Japan.

Shinya Kimura (S)

Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Nabeshima 5-1-1, Saga, Japan.

Eishi Ashihara (E)

Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, Kyoto, Japan. Electronic address: ash@mb.kyoto-phu.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH